Psychedelic Therapy’s $100B Moment: Why Compass Pathways’ COMP 360 Changes Investing
Compass Pathways’ stock jumped over 23% on positive Phase 3 psilocybin data — and Motley Fool analyst Sanmeet Deo sits down with Dr. Will Van Derveer and Keith Kurlander, founders of the Integrative Psychiatry Institute, to explain why they believe this isn’t hype but the birth of an entirely new healthcare category. They break down why psychedelic therapy is an interventional, therapy-paired treatment (not a daily pill), how the economics favor clinic services over the drug itself, and which signals investors should watch next.
Topics covered:
• Why Compass Pathways’ (CMPS) Phase 3 COMP 360 psilocybin results matter for the FDA pathway
• How psychedelic therapy differs from daily antidepressants — preparation, dosing, and integration
• The treatment-resistant depression opportunity and addressable market
• Where the real revenue lives: $10K–$20K per course clinic services vs. the drug
• Operational bottlenecks: multi-hour sessions, facility footprint, therapist training
• Competitive moats, IP for analogs, payer and reimbursement risks
• Lessons from Spravato’s ramp at Johnson & Johnson and what to watch in upcoming Phase 3 readouts
Dr. Will Van Derveer, MD and Keith Kurlander, MA, LPC — co-authors of Psychedelic Therapy: A Revolutionary Approach to Restoring Your Mental Health and Reclaiming Your Life — join Sanmeet Deo for this interview.
————————————————————————
This video is brought to you by The Motley Fool. Visit https://fool.com/Invest to get access to this special offer. The Motley Fool Stock Advisor returns are 972% as of 4/23/2026 and measured against the S&P 500 returns of 198% as of 4/23/2026. Past performance is not an indicator of future results. All investing involves a risk of loss. Individual investment results may vary, not all Motley Fool Stock Advisor picks have performed as well.
————————————————————————
